What drives HIV prevention choices for women who inject drugs?
NCT ID NCT05799339
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at how women who inject drugs view a long-acting injectable HIV prevention medication called CAB-LA. Researchers interviewed 144 women to understand what influences their decisions to use this option versus daily pills. The goal is to learn how to better support this group in preventing HIV.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cabotegravir (CAB-LA) long-acting injectable PrEP
- What this could lead to
- If successful, this research could help design better HIV prevention programs tailored for women who inject drugs.
- What could go wrong
- This is a small, completed study focused on gathering opinions and early engagement data, not testing effectiveness. Results may not apply to all populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Prevention Point Philadelphia
Philadelphia, Pennsylvania, 19143, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop anal lesions from becoming cancer?
- Can a 5-Pill opioid prescription match a 30-Pill one after hip surgery?
- Hidden risk: could opioid misuse be overlooked in cancer care?
- Can mindfulness curb opioid use after injury?
- Can resilience defeat HIV stigma? a new study investigates
- Peer support may curb HIV stigma and stress in vietnamese gay men